LONG-TERM OUTCOMES OF HYPERTENSIVE PATIENTS TREATED WITH ACE INHIBITORS VERSUS ARBS: A COMPARATIVE STUDY
DOI:
https://doi.org/10.53350/Annalspakmed.1.1.4Keywords:
Hypertension, ACE inhibitors, ARBs, Cardiovascular events, Long-term outcomesAbstract
Introduction: The cornerstone of hypertension management often involves pharmacological intervention aimed at lowering blood pressure to reduce associated risks.
Objectives: The main objective of the study is to find the comparison of long-term outcomes of hypertensive patients treated with ACE inhibitors versus ARBs.
Methodology of the Study: This comparative study was conducted in Services hospital Lahore from 1st July 2023 to 31st December 2023. A total of 260 patients aged > 18 years were included in the study. All those participants who do not want to participate in the study were excluded. Demographic information, clinical characteristics, comorbidities, medication history, and laboratory parameters were extracted from the hospital record of eligible patients. Baseline characteristics included age, sex, body mass index (BMI), smoking status, systolic and diastolic blood pressure levels, duration of hypertension, and presence of diabetes mellitus, chronic kidney disease, or cardiovascular disease.
Results: Data were collected from 260 patients. Mean age of the patients in group I was 58.10 ± 9.87 years and in group II 57.65 ± 10.21 years. There were 55% male and 45% female patients. 30% patients also suffer from DM, 15% from CKD and 20% from CVD. ACE inhibitor group exhibited a 20% incidence of cardiovascular events, slightly higher than the 15% observed in the ARB group, although this difference was not statistically significant (p = 0.23).
Conclusion: It is concluded that our study did not find statistically significant differences in long-term outcomes between hypertensive patients treated with ACE inhibitors versus ARBs, trends suggest potential benefits of ARBs in medication adherence. Despite this, both drug classes demonstrated comparable efficacy and safety profiles in reducing cardiovascular and renal risks.
References
1. Chen, R., Suchard, M. A., Krumholz, H. M., Schuemie, M. J., Shea, S., Duke, J., & Hripcsak, G. (2021). Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension, 78(3), 591-603.
2. Lee, J. G., Joo, S. J., Kim, S. Y., Choi, J. H., Boo, K. Y., Hwang, J. Y, & KAMIR-NIH investigators. (2023). Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction. Plos one, 18(3), e0281460.
3. Her, A. Y., Choi, B. G., Rha, S. W., Kim, Y. H., Choi, C. U., & Jeong, M. H. (2020). The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. Plos one, 15(11), e0242314.
4. Powers BJ, Coeytaux RR, Dolor RJ, Hasselblad V, Patel UD, Yancy WS Jr, Gray RN, Irvine RJ, Kendrick AS, Sanders GD. Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. J Gen Intern Med. 2012 Jun;27(6):716-29. doi: 10.1007/s11606-011-1938-8. Epub 2011 Dec 7. PMID: 22147122; PMCID: PMC3358398.
5. Peresuodei TS, Gill A, Orji C, Reghefaoui M, Saavedra Palacios MS, Nath TS. A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review. Cureus. 2024 Feb 16;16(2):e54311. doi: 10.7759/cureus.54311. PMID: 38496070; PMCID: PMC10944326.
6. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. Xie W, Zheng F, Evangelou E, et al. J Hypertens. 2018;36:1256–1265.
7. Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis. Salvador GL, Marmentini VM, Cosmo WR, Junior EL. Eur J Prev Cardiol. 2017;24:1914–1924.
8. Wu H-Y, Peng C-L, Chen P-C, Chiang C-K, Chang C-J, Huang J-W, et al. (2017) Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: A 15-year cohort study. PLoS ONE 12(5): e0177654. https://doi.org/10.1371/journal.pone.0177654
9. Her, A. Y., Choi, B. G., Rha, S. W., Kim, Y. H., Choi, C. U., & Jeong, M. H. (2020). The impact of angiotensin-converting-enzyme inhibitors versus angiotensin receptor blockers on 3-year clinical outcomes in patients with acute myocardial infarction without hypertension. Plos one, 15(11), e0242314.
10. Zhang, Y., Ding, X., Hua, B., Liu, Q., Chen, H., Zhao, X. Q., ... & Li, H. (2020). Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome. Journal of Translational Medicine, 18, 1-13.
11. Cavero-Redondo, I., Saz-Lara, A., Lugones-Sánchez, C., Pozuelo-Carrascosa, D. P., Gómez-Sánchez, L., López-Gil, J. F., ... & Gómez-Marcos, M. Á. (2023). Comparative effect of antihypertensive drugs in improving arterial stiffness in adults with hypertension (RIGIPREV study). A network meta-analysis. Frontiers in Pharmacology, 14, 1225795.
12. Jeong, H. S., Lim, H. S., Park, H. J., Lee, W. S., Choi, J. O., Lee, H. S., ... & Hong, S. J. (2021). Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up. Scientific Reports, 11(1), 1783.
13. Fu, E. L., Clase, C. M., Evans, M., Lindholm, B., Rotmans, J. I., Dekker, F. W., ... & Carrero, J. J. (2021). Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: a nationwide observational cohort study. American Journal of Kidney Diseases, 77(5), 719-729.
14. Yao, J., Fan, S., Shi, X., Gong, X., Zhao, J., & Fan, G. (2021). Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers on insulin sensitivity in hypertensive patients: A meta-analysis of randomized controlled trials. PloS one, 16(7), e0253492.
15. Chen, C. W., Chang, C. W., Lin, Y. C., Chen, W. T., Chien, L. N., & Huang, C. Y. (2023). Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction. PLoS One, 18(9), e0290251.
16. Lee, W., Kang, J., Park, J. B., Seo, W. W., Lee, S. Y., Lim, W. H., ... & Kim, H. L. (2023). Long‐term mortality and cardiovascular events of seven angiotensin receptor blockers in hypertensive patients: Analysis of a national real‐world database: A retrospective cohort study. Health Science Reports, 6(2), e1056.
17. Kim, H. L., Hwang, D., Lee, J. H., Lee, H. Y., Ihm, S. H., Kim, K. I., ... & Sung, K. C. (2022). Diuretics versus others for long-term clinical outcomes as first-line antihypertensive medications: analysis of national real-world database. Hypertension Research, 45(5), 758-768.
18. Chen, S. W., Chan, Y. H., Lin, C. P., Wu, V. C. C., Cheng, Y. T., Chen, D. Y., ... & Chou, A. H. (2021). Association of long-term use of antihypertensive medications with late outcomes among patients with aortic dissection. JAMA Network Open, 4(3), e210469-e210469.
19. Tan, N. Y., Sangaralingham, L. R., Sangaralingham, S. J., Yao, X., Shah, N. D., & Dunlay, S. M. (2020). Comparative effectiveness of sacubitril-valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction. JACC: Heart Failure, 8(1), 43-54.
20. Chan You, S., Krumholz, H. M., Suchard, M. A., Schuemie, M. J., Hripcsak, G., Chen, R, & Park, S. (2021). Comprehensive comparative effectiveness and safety of first-line β-blocker monotherapy in hypertensive patients: a large-scale multicenter observational study. Hypertension, 77(5), 1528-1538.
